PROTAC GSK-3β Degrader-1

PROTAC GSK-3β Degrader-1 (compound 1) is a degrader targets GSK-3β degradation with an IC50 value of 833 nM. PROTAC GSK-3β Degrader-1 contains SB-216763 (a GSK-3β inhibitor), a PEG linker and a CRBN (E3 ligase liand) . PROTAC GSK-3β Degrader-1 reduces the neurotoxicity induced by Aβ25-35 peptide and CuSO4. PROTAC GSK-3β Degrader-1 can be used to research in Alzheimer's disease[1].

Product Specifications

UNSPSC

12352005

Target

GSK-3; PROTACs

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR; PROTAC; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/protac-gsk-3β-degrader-1.html

Purity

99.05

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC1=CC(Cl)=CC=C1C(C(NC2=O)=O)=C2C3=CN(C4=CC=CC=C34)CC(NCCCOCCCCOCCCNC5=C(C6=CC=C5)C(N(C6=O)C7CCC(NC7=O)=O)=O)=O

Molecular Formula

C43H42Cl2N6O9

Molecular Weight

857.73

References & Citations

[1]Guardigni M, et al. PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer's Disease. ACS Chem Neurosci. 2023 Jun 7;14 (11) :1963-1970.